Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology

TFT Bioreactor image for PR

Mass-production of human induced pluripotent stem cells in a 10L bioreactor using TreeFrog Therapeutics’ C-Stem™ technology. Photo credits: TreeFrog Therapeutics

Format

JPEG

Source

Umoja Biopharma, Inc.

Téléchargements